I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| non-classical monocyte | 21 studies | 39% ± 14% | |
| classical monocyte | 11 studies | 22% ± 7% | |
| monocyte | 4 studies | 22% ± 6% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| non-classical monocyte | 21 studies | 39% ± 14% | |
| classical monocyte | 11 studies | 22% ± 7% | |
| monocyte | 4 studies | 22% ± 6% |
Insufficient scRNA-seq data for expression of LILRA1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 67% | 68.07 | 1761 / 2642 | 84% | 3.29 | 591 / 705 |
| lung | 99% | 442.81 | 575 / 578 | 40% | 0.75 | 459 / 1155 |
| kidney | 64% | 54.83 | 57 / 89 | 69% | 2.11 | 622 / 901 |
| breast | 76% | 53.84 | 348 / 459 | 35% | 0.63 | 393 / 1118 |
| spleen | 100% | 2287.10 | 241 / 241 | 0% | 0 | 0 / 0 |
| intestine | 78% | 57.77 | 754 / 966 | 21% | 0.38 | 111 / 527 |
| adrenal gland | 91% | 76.64 | 236 / 258 | 4% | 0.08 | 10 / 230 |
| prostate | 81% | 80.16 | 198 / 245 | 13% | 0.21 | 66 / 502 |
| adipose | 94% | 118.44 | 1129 / 1204 | 0% | 0 | 0 / 0 |
| bladder | 76% | 69.29 | 16 / 21 | 16% | 0.29 | 79 / 504 |
| peripheral blood | 89% | 3261.40 | 829 / 929 | 0% | 0 | 0 / 0 |
| liver | 78% | 72.69 | 176 / 226 | 8% | 0.14 | 31 / 406 |
| stomach | 46% | 33.93 | 165 / 359 | 34% | 0.63 | 97 / 286 |
| lymph node | 0% | 0 | 0 / 0 | 72% | 3.79 | 21 / 29 |
| uterus | 60% | 34.27 | 102 / 170 | 11% | 0.20 | 52 / 459 |
| pancreas | 36% | 22.84 | 118 / 328 | 34% | 0.57 | 61 / 178 |
| thymus | 54% | 29.95 | 352 / 653 | 13% | 0.22 | 76 / 605 |
| esophagus | 44% | 29.47 | 643 / 1445 | 20% | 0.40 | 37 / 183 |
| blood vessel | 63% | 53.68 | 838 / 1335 | 0% | 0 | 0 / 0 |
| ovary | 28% | 14.14 | 50 / 180 | 29% | 0.50 | 124 / 430 |
| heart | 48% | 29.11 | 409 / 861 | 0% | 0 | 0 / 0 |
| skin | 7% | 2.47 | 118 / 1809 | 37% | 0.92 | 174 / 472 |
| tonsil | 0% | 0 | 0 / 0 | 31% | 0.58 | 14 / 45 |
| muscle | 8% | 3.08 | 68 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 3% | 0.03 | 2 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0002250 | Biological process | adaptive immune response |
| GO_0002764 | Biological process | immune response-regulating signaling pathway |
| GO_0140105 | Biological process | interleukin-10-mediated signaling pathway |
| GO_0006952 | Biological process | defense response |
| GO_0007166 | Biological process | cell surface receptor signaling pathway |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0004888 | Molecular function | transmembrane signaling receptor activity |
| GO_0003823 | Molecular function | antigen binding |
| GO_0032396 | Molecular function | inhibitory MHC class I receptor activity |
| Gene name | LILRA1 |
| Protein name | Leukocyte immunoglobulin-like receptor subfamily A member 1 (CD85 antigen-like family member I) (Leukocyte immunoglobulin-like receptor 6) (LIR-6) (CD antigen CD85i) Leukocyte immunoglobulin-like receptor subfamily A member 1 |
| Synonyms | LIR6 |
| Description | FUNCTION: May act as receptor for class I MHC antigens. |
| Accessions | O75019 ENST00000251372.8 [O75019-1] ENST00000620606.4 [O75019-2] ENST00000613536.4 ENST00000453777.1 [O75019-2] ENST00000631007.1 [O75019-2] ENST00000617170.4 [O75019-1] ENST00000628480.1 [O75019-2] ENST00000616368.4 A0A0G2JP96 |
